175 related articles for article (PubMed ID: 11235727)
1. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
[TBL] [Abstract][Full Text] [Related]
2. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
3. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced thrombocytopenia type II in an infant with a congenital heart defect--anticoagulation during cardiopulmonary bypass with epoprostenol sodium and heparin.
von Heymann C; Hagemeyer E; Kastrup M; Ziemer S; Proquitté H; Konertz WF; Spies C
Pediatr Crit Care Med; 2006 Jul; 7(4):383-5. PubMed ID: 16738494
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
Gitlin SD; Deeb GM; Yann C; Schmaier AH
J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
[TBL] [Abstract][Full Text] [Related]
6. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
[TBL] [Abstract][Full Text] [Related]
8. Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients.
Sodian R; Loebe M; Gorman KF; Riess H; Hetzer R
ASAIO J; 1997; 43(5):M430-3. PubMed ID: 9360077
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
10. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
11. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
12. Successful use of danaparoid in two pregnant women with heart valve prosthesis and heparin-induced thrombocytopenia Type II (HIT).
Gerhardt A; Scharf RE; Zotz RB
Clin Appl Thromb Hemost; 2009; 15(4):461-4. PubMed ID: 18840630
[TBL] [Abstract][Full Text] [Related]
13. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
14. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Olin DA; Urdaneta F; Lobato EB
J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
[No Abstract] [Full Text] [Related]
15. [Cardiac surgery in patients with heparin-induced thrombocytopenia (HIT II)].
Jović MD; Nezić DG; Calija BM; Nenadić DS; Knezević AM; Borzanović MD; Krivokapić BM; Petrović IM; Djukanović BP
Acta Chir Iugosl; 2009; 56(1):47-52. PubMed ID: 19504989
[TBL] [Abstract][Full Text] [Related]
16. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
[TBL] [Abstract][Full Text] [Related]
17. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
[TBL] [Abstract][Full Text] [Related]
18. Coronary artery bypass grafting in a patient with type II heparin associated thrombopenia.
Christiansen S; Geiger A; Splittgerber FH; Reidemeister JC
Cardiovasc Surg; 1998 Feb; 6(1):90-3. PubMed ID: 9546852
[TBL] [Abstract][Full Text] [Related]
19. Aprotinin and organon 10172: a successful combination for coronary artery bypass surgery complicated by heparin-induced thrombocytopenia.
Alvarez MJ; Mezzatesta PJ
Aust N Z J Surg; 2000 Nov; 70(11):819-21. PubMed ID: 11147447
[No Abstract] [Full Text] [Related]
20. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
Horlait G; Minet V; Mullier F; Michaux I
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):193-197. PubMed ID: 27100305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
